RxDoctor Payments Data

Michel Yadegari, MD

Gastroenterology · Los Angeles, CANPI 1023293016

Payments from drug & device makers

$653in general payments, 2019–2025

Across 32 payments — averaging $20.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$448
  • Biohaven Pharmaceutical Holding Company Ltd.$24
  • Titan Pharmaceuticals, Inc.$23
  • Hologic Sales And Service, LLC$22
  • Amgen$20
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$20
  • plus $95 from 6 others

What the payments were for

  • Food & beverage$653100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$653 in reported general payments places this provider in the 30th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$5,192
Medicare patients
26
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin35$19,677
TrulicityDulaglutide19$18,171
JanumetSitagliptin Phos/Metformin Hcl22$11,149
FarxigaDapagliflozin Propanediol11$8,591
VascepaIcosapent Ethyl56$8,379
Incruse ElliptaUmeclidinium Bromide19$6,442
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,377
Arnuity ElliptaFluticasone Furoate16$3,924
Albuterol Sulfate HfaAlbuterol Sulfate95$3,146
Mesalamine ErMesalamine12$2,731
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl22$1,983
Ketoconazole40$1,195
Tolterodine Tartrate ErTolterodine Tartrate14$1,110
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$947
FenofibrateFenofibrate,micronized46$927

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$14$18,17119 claims
MerckJanumet$13$11,14922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →